| Literature DB >> 24836306 |
Donatella Paolino1, Donato Cosco1, Marco Gaspari2, Marilena Celano3, Joy Wolfram4, Pasquale Voce5, Efisio Puxeddu5, Sebastiano Filetti6, Christian Celia7, Mauro Ferrari8, Diego Russo9, Massimo Fresta10.
Abstract
Various tissue-specific antibodies have been attached to nanoparticles to obtain targeted delivery. In particular, nanodelivery systems with selectivity for breast, prostate and cancer tissue have been developed. Here, we have developed a nanodelivery system that targets the thyroid gland. Nanoliposomes have been conjugated to the thyroid-stimulating hormone (TSH), which binds to the TSH receptor (TSHr) on the surface of thyrocytes. The results indicate that the intracellular uptake of TSH-nanoliposomes is increased in cells expressing the TSHr. The accumulation of targeted nanoliposomes in the thyroid gland following intravenous injection was 3.5-fold higher in comparison to untargeted nanoliposomes. Furthermore, TSH-nanoliposomes encapsulated with gemcitabine showed improved anticancer efficacy in vitro and in a tumor model of follicular thyroid carcinoma. This drug delivery system could be used for the treatment of a broad spectrum of thyroid diseases to reduce side effects and improve therapeutic efficacy.Entities:
Keywords: Nanoliposomes; Nanoparticles; Targeting; Thyroid cancer; Thyroid gland
Mesh：
Substances：
Year: 2014 PMID： 24836306 DOI： 10.1016/j.biomaterials.2014.04.088
Source DB: PubMed Journal: Biomaterials ISSN： 0142-9612 Impact factor: 12.479